High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.

ABSTRACT: Microtubule-associated protein 7 (MAP7) plays an important role in cancer cells. In this study, we identified the prognostic significance of MAP7 expression in cytogenetically normal acute myeloid leukemia (CN-AML) patients (aged <60 years) based on several microarray datasets. In the first group (n?=?129), high MAP7 expression (MAP7(high)) was associated with adverse overall survival (OS; P?=?0.0441) and event-free survival (EFS; P?=?0.0114) compared with low MAP7 expression (MAP7(low)). In addition, the prognostic significance of MAP7 was confirmed by European Leukemia Net (ELN) intermediate-I genetic categories and multivariable analysis. In the second independent group of CN-AML patients (aged <60 years), MAP7(high) was also associated with adverse OS (n?=?88, OS; P?=?0.00811). To understand the inherent mechanisms of MAP7's prognosis, we investigated genome-wide gene/microRNA expression signatures associated with MAP7 expression. Several known oncogenic genes/microRNAs and anti-oncogenic genes/microRNAs were disordered in MAP7(high) CN-AML patients. In conclusion, MAP7(high) is an adverse prognostic biomarker for CN-AML, which may be attributed to the distinctive genome-wide gene/microRNA expression and related cell signaling pathways.

SUBMITTER: Fu L 

PROVIDER: S-EPMC5043276 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature